89bio Inc Stock Analysis

89bio Stock Analysis Notes

About 94.0% of the company shares are held by institutions such as insurance companies. The book value of 89bio was currently reported as 3.56. The company recorded a loss per share of 2.96. 89bio Inc had not issued any dividends in recent years. 89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. The company also intends to develop pegozafermin for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California. 89Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 41 people. To learn more about 89bio Inc call Rohan Palekar at 415 432 9270 or check out https://www.89bio.com.

89bio Inc Investment Alerts

89bio Inc Upcoming and Recent Events

89bio Largest EPS Surprises

View All Earnings Estimates

89bio Environmental, Social, and Governance (ESG) Scores

89bio Stock Institutional Investors

Note, although 89bio's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

89bio Market Capitalization

The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.07 B.

89bio Profitablity

Management Efficiency

89bio Inc has return on total asset (ROA) of (0.4136) % which means that it has lost $0.4136 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7331) %, meaning that it created substantial loss on money invested by shareholders. 89bio's management efficiency ratios could be used to measure how well 89bio manages its routine affairs as well as how well it operates its assets and liabilities. As of November 29, 2024, Return On Tangible Assets is expected to decline to -0.25. In addition to that, Return On Capital Employed is expected to decline to -0.28. At present, 89bio's Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 2.9 M, whereas Net Tangible Assets are forecasted to decline to about 122 M.

Technical Drivers

As of the 29th of November, 89bio shows the Coefficient Of Variation of 5164.52, market risk adjusted performance of 0.0346, and Mean Deviation of 2.69. 89bio Inc technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the entity's future prices.

89bio Inc Price Movement Analysis

89bio Inc Insider Trading Activities

89bio Outstanding Bonds

89bio Predictive Daily Indicators

89bio Corporate Filings

89bio Forecast Models

89bio's time-series forecasting models are one of many 89bio's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary 89bio's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how 89bio prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling 89bio shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as 89bio. By using and applying 89bio Stock analysis, traders can create a robust methodology for identifying 89bio entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. 89bio analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. 89bio analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

89bio Inc stock analysis indicators help investors evaluate how 89bio stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading 89bio shares will generate the highest return on investment. By understating and applying 89bio stock analysis, traders can identify 89bio position entry and exit signals to maximize returns.

When running 89bio's price analysis, check to measure 89bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy 89bio is operating at the current time. Most of 89bio's value examination focuses on studying past and present price action to predict the probability of 89bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move 89bio's price. Additionally, you may evaluate how the addition of 89bio to your portfolios can decrease your overall portfolio volatility.